Friedreich Ataxia Drug Market
Friedreich Ataxia Drug Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Friedreich Ataxia Drug Market Size and Growth
The Friedreich Ataxia drug market is expanding, driven by rising prevalence and ongoing clinical trials. Recent research indicates a market size of approximately $320 million, with expectations for significant growth due to advancements in therapies and increased investment in research, enhancing treatment options for affected individuals. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Adverum Biotechnologies Inc
◍ BioMarin Pharmaceutical Inc.
◍ Biovista Inc.
◍ Cardero Therapeutics Inc
◍ Catabasis Pharmaceuticals, Inc.
◍ Forward Pharma A/S
◍ Ixchel Pharma LLC
◍ Pfizer Inc
◍ ProQR Therapeutics NV
◍ RaNA Therapeutics Inc
◍ Reata Pharmaceuticals Inc
◍ Retrotope Inc
◍ Takeda
◍ STATegics Inc
◍ Voyager Therapeutics Inc
The Friedreich Ataxia drug market features companies like Adverum, BioMarin, and Reata, focusing on gene therapies and small molecules. These firms drive innovation and clinical trials, expanding treatment options. For example, BioMarin reported $900 million in revenue. Their advancements foster growth and awareness in this niche therapeutic area.
Request Sample Report
Market Segmentation
By Application
Clinic
Hospital
Others
Request Sample Report
By Product
ADVM-063
AGIL-FA
BHV-4157
BVA-202
Others
Market Growth
Request Sample Report
$ X Billion USD
